Vozeh S, Uematsu T, Ritz R, Schmidlin O, Kaufman G, Scholer A, Follath F
Am Heart J. 1987 Apr;113(4):928-33. doi: 10.1016/0002-8703(87)90053-6.
The performance of a computerized dosing aid in achieving a target serum concentration of lidocaine in the middle of the recommended therapeutic range (3.5 mg/L) was evaluated in 63 patients treated for acute ventricular arrhythmias. In all patients a serum concentration measurement was obtained shortly after starting lidocaine infusion. In 22 patients a microcomputer program based on a Bayesian forecasting technique was used for dosing recommendations, whereas in 41 the serum concentration was interpreted and the dose was adjusted by the unaided physician. Both groups were similar with respect to the average concentration achieved (control: 3.8 +/- 1.13 [SD] mg/L, computer-aided: 3.5 +/- 0.59 mg/L). However, the interindividual variability was significantly larger in the control group (95% confidence interval: 1.5 to 6.1 mg/L vs 2.3 to 4.7 mg/L [p less than 0.01]). Nine of the 41 patients in the control group had a lidocaine concentration outside the recommended therapeutic range of 2 to 5 mg/L compared to only 1 of 22 in the computer-aided group. Lidocaine concentrations greater than 2 mg/L were associated with significantly more effective suppression of ventricular arrhythmias (p less than 0.05). The results show that Bayesian forecasting outperforms the physician in early adjustment of lidocaine dosage based on serum concentration measurements.
在63例接受急性室性心律失常治疗的患者中,评估了一种计算机化给药辅助工具在达到推荐治疗范围中间值(3.5毫克/升)的利多卡因目标血清浓度方面的性能。在所有患者中,在开始输注利多卡因后不久即进行血清浓度测量。22例患者使用基于贝叶斯预测技术的微型计算机程序进行给药建议,而41例患者由医生在不借助辅助工具的情况下解读血清浓度并调整剂量。两组在达到的平均浓度方面相似(对照组:3.8±1.13[标准差]毫克/升,计算机辅助组:3.5±0.59毫克/升)。然而,对照组的个体间变异性显著更大(95%置信区间:1.5至6.1毫克/升,相比之下计算机辅助组为2.3至4.7毫克/升[p<0.01])。对照组41例患者中有9例的利多卡因浓度超出了2至5毫克/升的推荐治疗范围,而计算机辅助组22例中只有1例。利多卡因浓度大于2毫克/升与更有效地抑制室性心律失常显著相关(p<0.05)。结果表明,在基于血清浓度测量早期调整利多卡因剂量方面,贝叶斯预测比医生表现更优。